Kristen Garofalo
Advanced Heart Failure and Transplant Cardiology · Newark, NJNPI 1063062933
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 305 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,493, more than ten times the $36 reported in 2020. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in NJ, where the typical reported total is $7,482.
Across 305 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AOP Health US, LLC$797
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$767
- AstraZeneca$736
- Actelion Pharmaceuticals US, Inc.$723
- Boehringer Ingelheim$574
- Merck$477
- plus $2K from 21 others
What the payments were for
- Food & beverage$6,379100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AOP Health US, LLC | 1 | $797 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 27 | $767 |
| AstraZeneca | 44 | $736 |
| Actelion Pharmaceuticals US, Inc. | 41 | $723 |
| Boehringer Ingelheim | 38 | $574 |
| Merck | 29 | $477 |
| Alnylam Pharmaceuticals Inc. | 27 | $444 |
| Pfizer | 25 | $401 |
| Bayer | 17 | $258 |
| Impulse Dynamics (USA) Inc. | 5 | $254 |
| Novartis | 7 | $127 |
| Lexicon Pharmaceuticals, Inc. | 6 | $107 |
| Amgen | 7 | $107 |
| United Therapeutics Corporation | 6 | $101 |
| Bridgebio Pharma, Inc. | 5 | $95 |
| Scpharmaceuticals Inc. | 4 | $83 |
| Boston Scientific | 3 | $75 |
| Baxter Healthcare | 2 | $74 |
| Cvrx, Inc. | 2 | $44 |
| Johnson & Johnson | 2 | $23 |
| Astellas Pharma US Inc | 1 | $19 |
| Edwards Lifesciences | 1 | $18 |
| Sanofi | 1 | $18 |
| Kestra Medical Technology Services, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| GSK | 1 | $14 |
| Nuwellis, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,379 in reported general payments places this provider in the 40th percentile of 21 advanced heart failure and transplant cardiology providers in New Jersey.
See all advanced heart failure and transplant cardiology providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 48 | $1,119,172 |
| EntrestoSacubitril/Valsartan | 62 | $70,875 |
| FarxigaDapagliflozin Propanediol | 45 | $40,628 |
| JardianceEmpagliflozin | 15 | $25,845 |
| EliquisApixaban | 14 | $18,024 |
| Spironolactone | 82 | $1,143 |
| Valsartan | 23 | $660 |
| Torsemide | 13 | $560 |
| Metoprolol Succinate | 19 | $507 |
| Amiodarone Hcl | 15 | $285 |
| Bisoprolol Fumarate | 11 | $280 |
| Atorvastatin Calcium | 12 | $263 |
| Carvedilol | 20 | $247 |
| Furosemide | 14 | $59 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $401 | $1,137,19662 claims |
| NovartisEntresto | $127 | $70,87562 claims |
| AstraZenecaFarxiga | $736 | $40,62845 claims |
| Boehringer IngelheimJardiance | $574 | $25,84515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 21 advanced heart failure and transplant cardiology providers in New Jersey.
Other advanced heart failure and transplant cardiology in Newark
- Eman RashedNewark$7K
- Pallavi SolankiNewark$2K
- Abhishek SinghMorristown$283K
- Kanika ModyHackensack$107K
- Kulpreet BarnBarnegat$92K
- Robert MohapatraSewell$84K
- Saad AhmadMorristown$74K
- Mark ZuckerMorristown$44K
- Saurabh KapoorEnglewood$27K
- Ketan GalaCherry Hill$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.